GENinCode (LON:GENI) Trading 8.7% Higher – What’s Next?

GENinCode Plc (LON:GENI)’s stock price rose 8.7% on Tuesday . The stock traded as high as GBX 0.98 and last traded at GBX 0.98. 3,765,810 shares traded hands during trading, a decline of 41% from the average daily volume of 6,361,748 shares. The stock had previously closed at GBX 0.90.

GENinCode Trading Up 8.7%

The stock’s 50 day moving average price is GBX 1.10 and its 200-day moving average price is GBX 1.45. The company has a quick ratio of 15.88, a current ratio of 0.93 and a debt-to-equity ratio of 117.74. The stock has a market capitalization of £7.09 million, a PE ratio of -0.42 and a beta of 0.59.

GENinCode (LON:GENI) last released its earnings results on Monday, June 8th. The company reported GBX (2.08) earnings per share for the quarter. The firm had revenue of GBX 308 million for the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. On average, sell-side analysts expect that GENinCode Plc will post -7.1299999 earnings per share for the current fiscal year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.